$AKTS insider trading

Over the last 12 months, Aktis Oncology insiders reported 6 buys totaling $114.3M and 4 sales totaling $3.0M across SEC Form 4 filings.

$114.3M
$3.0M
10
9
0%
Side
$10K$100K$1.0M$10MJun '26JulAugSep
Herrmann Ken
EcoR1 Capital, LLC
MPM BIOVENTURES 2018, L.P.
GADICKE ANSBERT
Vida Ventures II, LLC

All insider trades

Scroll the table sideways for price, value and marks.

Jul 20, 2026Herrmann Ken▼ Sale4,856$24.56$119K-100%
Jul 17, 2026Herrmann Ken▼ Sale3,065$25.21$77K-100%
Jul 8, 2026Ron-Bigger Shulamit▼ Sale50,000$27.75$1.4M-100%
Jul 8, 2026Czibere Akos▼ Sale50,000$27.77$1.4M-100%
Jan 12, 2026Foley Todd▲ Buy232,870$18$4.2M+5.8%
Jan 12, 2026MPM BIOVENTURES 2018, L.P.▲ Buy1,112,777$18$20.0M+12.2%
Jan 12, 2026GADICKE ANSBERT▲ Buy1,112,777$18$20.0M+12.2%
Jan 12, 2026Vida Ventures II, LLC▲ Buy835,000$18$15.0M
Jan 12, 2026Kim Helen Susan▲ Buy835,000$18$15.0M
Jan 12, 2026EcoR1 Capital, LLC▲ Buy2,222,222$18$40.0M

Every $AKTS filing on this page is one API call away

The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Aktis Oncology filings can reach your inbox instead.

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AKTS feed.

AKTS Insider Trading — Aktis Oncology Form 4 Buys & Sells | alphai